Sildenafil contraindications are specific situations identified in approved prescribing information in which the drug should not be used. In current U.S. sildenafil tablet labeling, the core contraindication categories include concomitant use of nitric oxide donors such as organic nitrates or nitrites, concomitant use of guanylate cyclase stimulators such as riociguat, and known hypersensitivity to sildenafil or relevant product components.
A contraindication is not the same as a warning, precaution or drug interaction that merely requires additional assessment. Cardiovascular status, alpha-blocker or antihypertensive therapy, organ impairment, CYP-mediated interactions and risks such as priapism or sudden sensory changes can be clinically important without automatically belonging to the formal Contraindications section.
This page provides a label-based map of those distinctions. It summarizes the main sildenafil contraindications while leaving detailed interaction mechanisms, cardiovascular precautions and product-specific prescribing decisions to their dedicated resources and the official label for the product involved.
A contraindication is a defined circumstance in which prescribing information states that a medicine should not be used because the identified risk makes use inappropriate in that setting. It is a stronger regulatory category than a general precaution or warning.
For sildenafil, the principal U.S. tablet-label contraindications fall into three groups: nitric oxide donors such as organic nitrates or nitrites, guanylate cyclase stimulators such as riociguat, and known hypersensitivity to sildenafil or a relevant product component.
This distinction matters because many other safety issues appear elsewhere in prescribing information. A clinically important interaction, cardiovascular condition or organ-function change should not automatically be called a contraindication unless the applicable product label actually classifies it that way.
| Term | Meaning |
|---|---|
| Contraindication | Label-defined circumstance in which sildenafil should not be used. |
| Warning | Important risk that requires assessment or caution but is not automatically a contraindication. |
| Precaution | Clinical factor that can influence how the medicine is evaluated or used. |
| Side effect | Adverse reaction that may occur during treatment. |
Current U.S. sildenafil tablet labeling identifies three core contraindication categories. Two are interaction-based: concomitant use with nitric oxide donors such as organic nitrates or organic nitrites, and concomitant use with guanylate cyclase stimulators such as riociguat.
The third category is known hypersensitivity to sildenafil or, depending on the specific product labeling, a component of the formulation. Hypersensitivity reactions reported with sildenafil have included reactions such as rash or urticaria, while some PAH-oriented sildenafil labels also reference severe hypersensitivity reactions.
The core categories are broadly consistent across major U.S. tablet labeling contexts, but the exact wording and product-component language should always be checked against the prescribing information for the specific sildenafil product.
| Category | Label Context |
|---|---|
| Nitric oxide donors / organic nitrates or nitrites | Contraindicated because sildenafil can potentiate nitrate-related hypotensive effects. |
| Guanylate cyclase stimulators such as riociguat | Contraindicated because PDE5 inhibition can potentiate hypotensive effects. |
| Known hypersensitivity | Contraindicated in patients with known hypersensitivity to sildenafil or applicable product components. |
Sildenafil is contraindicated with nitric oxide donors such as organic nitrates or organic nitrites in any form. Current labeling applies this restriction whether nitrate exposure is regular or intermittent.
The pharmacological basis is additive activity within the nitric oxide–cGMP pathway. Sildenafil inhibits PDE5-mediated cGMP breakdown, while nitrates increase nitric oxide signaling; combining the two can substantially amplify blood-pressure-lowering effects.
The contraindication is stronger than a routine interaction warning. Sildenafil labeling also states that after sildenafil has been taken, the precise time at which nitrates could subsequently be administered safely is not established. The dedicated nitrate resource covers this interaction in greater depth.
| Topic | Context |
|---|---|
| Organic nitrates or nitrites | Contraindicated combination |
| Safety basis | Potentiation of hypotensive effects through overlapping nitric oxide–cGMP signaling |
| Regular or intermittent use | Both fall within the labeled contraindication |
| Deep dive | Sildenafil and Nitrates Interaction |
Current sildenafil labeling contraindicates concomitant use with guanylate cyclase stimulators such as riociguat. The restriction applies because both therapies can increase signaling within pathways that influence vascular tone and blood pressure.
Riociguat directly stimulates soluble guanylate cyclase, whereas sildenafil reduces PDE5-mediated degradation of cGMP. The resulting pharmacodynamic overlap can potentiate hypotensive effects.
The key point on this page is the regulatory classification: riociguat is not merely an interaction requiring routine monitoring but belongs to the formal contraindication category. Detailed mechanism and interaction context remain on the dedicated resource.
| Topic | Context |
|---|---|
| Riociguat | Guanylate cyclase stimulator and contraindicated combination |
| Mechanistic basis | Potentially amplified cGMP-mediated vascular effects |
| Regulatory category | Formal contraindication |
| Detailed resource | Sildenafil and Riociguat Interaction |
Contraindications and warnings appear in different sections of prescribing information because they communicate different levels and types of restriction. A contraindication identifies a circumstance in which sildenafil should not be used, while a warning identifies a significant risk requiring assessment, caution or specific action.
For ED-oriented sildenafil labeling, cardiovascular status provides a useful example. The label warns that patients should not use sildenafil when sexual activity is inadvisable because of cardiovascular status, but that statement appears under Warnings and Precautions rather than as one of the three formal Contraindications entries.
Other examples include priapism risk, sudden visual or hearing changes, hypotension with alpha-blockers or antihypertensives and increased exposure with strong CYP inhibitors. These issues are important, but calling all of them contraindications would make the page less accurate rather than more cautious.
| Concept | Meaning |
|---|---|
| Contraindication | Use should not occur in the defined label circumstance. |
| Warning | Significant risk requiring clinical attention or specific precautions. |
| Precaution | Factor that can change assessment, monitoring or use. |
| Dose or exposure consideration | May require modification without constituting a contraindication. |
Contraindications describe circumstances that exist before or during a prescribing decision and determine whether sildenafil should be used at all. Side effects, by contrast, are adverse reactions that can occur after exposure to the medicine.
A person can have no formal contraindication and still experience headache, flushing, dyspepsia, visual symptoms or another adverse reaction. Conversely, the absence of previous side effects does not remove a contraindication such as concurrent nitrate therapy.
Hypersensitivity illustrates an important boundary between the categories. A previous hypersensitivity reaction can become a reason the drug is formally contraindicated in that patient, whereas many other adverse reactions remain side-effect or warning information rather than contraindications.
| Question | Category |
|---|---|
| Is there a labeled reason sildenafil should not be used? | Contraindication |
| What reactions can occur after exposure? | Side effects / adverse reactions |
| What serious risks require caution or action? | Warnings and precautions |
| Can a prior hypersensitivity reaction affect future use? | Yes; known hypersensitivity is a contraindication |
Not every sildenafil drug interaction is a contraindication. Nitrates and guanylate cyclase stimulators such as riociguat are formal contraindication examples, but several other interacting drug classes are handled through warnings, precautions, exposure management or prescribing adjustments.
Alpha-blockers and antihypertensive medicines can contribute to hypotension and therefore require clinical consideration, but they are not automatically listed as sildenafil contraindications. Strong CYP inhibitors can substantially raise sildenafil exposure, yet current ED labeling addresses that issue through exposure and dosage guidance rather than classifying the entire interaction category as contraindicated.
Keeping these categories separate prevents an interaction database from being mistaken for a contraindication list. This page remains limited to formal contraindications, while dedicated interaction resources provide the broader medication-by-medication framework.
| Topic | Dedicated Page |
|---|---|
| Drug interactions | Sildenafil Drug Interactions |
| Nitrates | Sildenafil and Nitrates Interaction |
| Riociguat | Sildenafil and Riociguat Interaction |
Cardiovascular health is central to sildenafil safety assessment, but cardiovascular disease as a broad category is not listed as a universal sildenafil contraindication. The relevant question is the specific cardiovascular condition, the safety of the underlying activity and any interacting medication such as nitrate therapy.
ED-oriented prescribing information warns that sildenafil should not be used when sexual activity is inadvisable because of cardiovascular status. That is an important clinical restriction, but structurally it appears in the Warnings and Precautions section rather than the formal Contraindications section.
This distinction matters for accurate safety writing. A nitrate prescription in a cardiovascular patient can create a direct sildenafil contraindication, while another cardiovascular condition may instead require individualized assessment under the warning framework.
| Topic | Category |
|---|---|
| Concurrent nitrate use | Formal contraindication |
| Sexual activity inadvisable because of cardiovascular status | Warning / clinical restriction |
| Antihypertensive therapy | Interaction and hypotension consideration |
| Cardiovascular disease as a broad category | Not automatically a universal contraindication |
Renal and hepatic impairment can materially change sildenafil pharmacokinetics, but impaired organ function is not itself listed as a universal sildenafil contraindication. The safety and prescribing implications depend on product context, degree of impairment and measured changes in systemic exposure.
Severe renal impairment and mild-to-moderate hepatic impairment have both been associated with increased sildenafil exposure in pharmacokinetic studies. Those findings belong to dose, exposure and clinical-assessment frameworks rather than converting every patient with kidney or liver disease into a contraindicated population.
This separation is important for site architecture as well as clinical accuracy. The detailed PK consequences remain on the dedicated impairment pages rather than being duplicated as contraindications here.
| Topic | Related Page |
|---|---|
| Renal impairment PK | Sildenafil PK in Renal Impairment |
| Hepatic impairment PK | Sildenafil PK in Hepatic Impairment |
| PK variability | Sildenafil PK Variability |
Contraindications must ultimately be read from the prescribing information for the specific sildenafil product. Products can share the same active sildenafil moiety while differing in indication, dosage form, excipients and label organization.
Major current U.S. sildenafil tablet labels in both ED and PAH contexts consistently identify the same core categories of organic nitrates, riociguat or other applicable guanylate cyclase stimulators, and known hypersensitivity. However, wording around formulation components and surrounding warnings can differ by product.
For that reason, a general page can summarize the recurring sildenafil contraindication framework but should not imply that one web summary replaces the product label. The specific formulation and indication remain part of the regulatory context.
| Factor | Importance |
|---|---|
| Active ingredient | Creates the shared sildenafil pharmacology |
| Specific product | Defines the authoritative prescribing information |
| Formulation components | Relevant to product-specific hypersensitivity language |
| Indication | Shapes surrounding warnings and clinical context |
A contraindication list is intentionally narrower than the complete safety profile. Someone reading only the Contraindications section would not see every important sildenafil warning, adverse reaction, interaction, organ-function consideration or population-specific issue.
The opposite mistake is also possible: expanding every serious warning into a contraindication makes the terminology inaccurate. Official prescribing information separates these categories so clinicians can distinguish absolute label restrictions from risks that instead require assessment, monitoring or changes in use.
A reliable summary should therefore state the formal contraindications clearly, identify major boundaries with warnings and interactions, and defer to the official prescribing information for the full product-specific safety framework.
| Source | Purpose |
|---|---|
| Contraindications section | Defines circumstances in which the product should not be used |
| Warnings and precautions | Describes significant risks requiring clinical consideration |
| Drug-interaction section | Explains interaction mechanisms and management |
| Clinical assessment | Applies the product information to an individual situation |
Current U.S. sildenafil tablet labeling identifies three core categories: use with nitric oxide donors such as organic nitrates or nitrites, use with guanylate cyclase stimulators such as riociguat, and known hypersensitivity to sildenafil or relevant product components.
The principal contraindicated medication categories are nitric oxide donors such as organic nitrates or nitrites and guanylate cyclase stimulators such as riociguat. Other drug interactions may require caution or prescribing changes without being formal contraindications.
Yes. Current labeling contraindicates sildenafil in patients with known hypersensitivity to sildenafil or, depending on the specific product, relevant formulation components.
No. Cardiovascular status requires clinical assessment, and ED labeling warns against sildenafil use when sexual activity is inadvisable because of cardiovascular status. That warning is distinct from formal contraindications such as nitrate use.
Not automatically. Renal and hepatic impairment can change sildenafil exposure and may affect prescribing decisions, but they are generally addressed through pharmacokinetic and precaution information rather than as universal contraindications.
No. Some interactions, such as nitrates and riociguat, are contraindicated. Others, including alpha-blockers, antihypertensives or strong CYP inhibitors, are handled through warnings, precautions or exposure-management guidance depending on the product label.